Abstract
Introduction
The prescription of an effective and well-tolerated antituberculosis (TB) treatment regimen is an important step in the management of TB.
Objective
The aim of the present study was comparison between fixed-dose combination (FDC) anti-TB drugs and separate drug formula (SDF) not only in pulmonary tuberculosis (PTB) but also in extrapulmonary tuberculosis (EPTB).
Patients and methods
A total of 240 patients with TB were included in the present study: 122 patients had PTB and 118 had EPTB. Both patients with PTB and those with EPTB were divided into two groups according to receiving FDC or SDF. All patients had baseline clinical and laboratory data, including blood picture, liver function tests, renal function tests, erythrocyte sedimentation rate, uric acid, and chest radiography. Follow-up clinical, laboratory, and radiology assessments were done during the course of treatment. Patients who received FDC and those who received SDF were compared for clinical, laboratory, radiological improvement, and sputum conversion in PTB during the course of treatment; moreover, they were compared for drug tolerance, compliance with treatment, and development of adverse effects.
Results
Both FDC and SDF in PTB and EPTB had comparable effect with respect to clinical improvement, and also sputum conversion in PTB; significant change in liver function was observed in PTB among those who received FDC, but better radiological clearance was detected with SDF. Both regimens were comparable with respect to compliance and adverse effects, except for more gastric disturbance with FDC.
Conclusion
SDF is recommended in patients with borderline liver function, gastrointestinal troubles, and presence of extensive radiological infiltrate.
Article PDF
Similar content being viewed by others
References
WHO World Health Organization Global TB Programme 20 avenue Appia Geneva, Switzerland 27 CH-1211. 2016.
Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines:Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis 2016;63:e147–e195.
Menzies D, Elwood K. Treatment of tuberculosis disease. In:Menzies D, Ellis E, Long R, Pai M, Wong T, editors. Canadian Tuberculosis Standards. 7th ed. Ottawa, ON:Centre for Communicable Diseases and Infection Control, Public Health Agency of Canada; 2014.
Thwaites G, Fisher M, Hemingway C. British Infection Society guidelines for the diagnosis and treatment of tuberculosis of the central nervous system in adults and children. J Infect 2009;59:167–187.
Monedero I, Caminero JA. Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control:a review. Int J Tuberc Lung Dis 2011;15:433–439.
Lienhardt C, Cook SV, Burgos M. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis:the Study C randomized controlled trial. JAMA 2011;305:1415–1423.
Nunn AJ, Cook SV, Burgos M. Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis. Int J Tuberc Lung Dis 2014;18:1252–1254.
Global Tuberculosis Report. TB case notifications and treatment outcome. Geneva, Switzerland:World Health Organization; 2013.
Seaton A, Seaton D, Leitch AG. Crofton and Douglas ’s respiratory diseases. 4th ed. Oxford, UK:Blackwell; 1989. pp. 409–410.
Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance:a meta-analysis. Am J Med 2007;120:713–719.
Hassmiller KM. The association between smoking and tuberculosis. Salud Publica Mex 2006;48:201–216.
Bartacek A, Schütt D, Panosch B, Borek M, Rimstar 4-FDC Study Group. Comparison of a four-drug fixed-dose combination regimen with a single tablet regimen in smear-positive pulmonary tuberculosis. Int J Tuberc Lung Dis 2009;13:760–766.
Gravendeel JM, Asapa AS, Becx-Bleumink M, Vrakking HA. Preliminary results of an operational field study to compare side-effects, complaints and treatment results of a single-drug short-course regimen with a four-drug fixed-dose combination (4FDC) regimen in South Sulawesi, Republic of Indonesia. Tuberculosis (Edinb) 2003;83:183–186.
Gallardo CR, Rigau Comas D, Valderrama Rodríguez A, Roqué i Figuls M, Parker LA, Caylà J, et al. Fixed-dose combinations of drugs versus single-drug formulations for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2016; (5):1–142.
Yaranal PJ, Umashankar T, Harish SG. Hematological profile in pulmonary tuberculosis. Int J Health Rehabil Sci 2013;2:50–56.
Singh KJ, Ahulwalia G, Sharma SK, Saxena R, Chaudhary VP, Anant M. Significance of hematological manifestations in patients with tuberculosis. J Asso Physicians India 2001;49:788–794.
Goldenberg AS. Hematologic abnormalities and mycobacterial infection. In:Williams NR, Stuart GM, editors. Tuberculosis. Boston:Little, Brown Company; 1996. pp. 645–647.
Morris CD, Bird AR, Nell H. The hematological and biochemical changes in severe pulmonary tuberculosis. Q J Med 1989;73:1151–1159.
Tanzeela T, Bashir MB, Yaqoob M. Comparative efficacy of different laboratory technique used in diagnosis of tuberculosis in human population. J Med Sci 2001;2:137–144.
Wu JT, Chiu CT, Wei UF, Lai YF. Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment. Clinic (Sao Paulo) 2015;70:429–434.
Oliva VM, Cezario GAG, Cacto RA, Marcondes-Machado J. Pulmonary tuberculosis; haemotology, serum biochemistry and relationship with the disease condition. J Venom Anim Toxins Incl Trop Dis 2008;14:71–78.
Al-Marri MR, Kirkpatrick MB. Erythrocyte sedimentation rate in childhood tuberculosis:is it still worthwhile?. Int J Tuberc Lung Dis 2000;4:237–239.
Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Raviglione MC. Standard short-course chemotherapy for drug-resistant tuberculosis. JAMA:J Am Med Asso 2000;283:2537–2542.
Adebisi SA, Oluboyo PO, Okesina AB. Effect of drug-induced hyperuricemia on renal function in Nigerians with pulmonary tuberculosis. Afr J Med Med Sci 2000;29:297–300.
Edalo AS, Ali AE, Hajeltayed OE, Khalil YM, Ma Y. Evaluation of effect of antituberculous drugs on the liver and renal function tests in a Sudanese cohort. Asian J Pharm Clin Res 2012;5:61–63.
Prasad B, Bhutani H, Singh S. Study of the interaction between rifapentine and isoniazid under acid conditions. J Pharm Biomed Anal 2006;41:1438–1441.
Bhutani H, Singh S, Jindal KC, Chakraborti AK. Mechanistic explanation to the catalysis by pyrazinamide and ethambutol of reaction between rifampicin and isoniazid in anti-TB FDCs. J Pharm Biomed Anal 2005;39:892–899.
Author information
Authors and Affiliations
Corresponding author
Additional information
This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
Rights and permissions
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
El-Kholy, M.M., Sadek, S.H. & Mahran, O. Fixed-dose combination versus separate drug formula for pulmonary and extrapulmonary tuberculosis. Egypt J Bronchol 12, 346–351 (2018). https://doi.org/10.4103/ejb.ejb_61_17
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.4103/ejb.ejb_61_17